Cervical cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

24 of 29+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, United States· US$762,815 awarded in fiscal year 2026· until Jun 2031

• NIH NCI · R01

  Enhancing Cervical Cancer Screening through Integrated Care in Rural North Carolina

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$607,403 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Comparative Modeling to Inform Cervical Cancer Prevention Policies and Practice in the United States

  Tulane University of Louisiana· New Orleans, United States· US$1,084,939 awarded in fiscal year 2026· until Aug 2031

• NIH NIDCR · R56

  Screening for HPV-related oropharyngeal cancer

  Johns Hopkins University· Baltimore, United States· US$979,697 awarded in fiscal year 2026· until Sept 2028

• NIH NCCIH · R34

  Feasibility Study to Increase use of non-Pharmacological Therapies for Chronic Low Back Pain

  Rand Corporation· Santa Monica, United States· US$757,923 awarded in fiscal year 2026· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,493,450· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €6,602,445· until Dec 2029· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spain· EU contribution €3,613,288· until May 2028· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €1,996,250· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norway· EU contribution €7,984,441· until Aug 2027· 6 countries

10 of 326 running projects, newest first. Listed amounts together: US$202.2m + €23.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

  NCT06865677· National Cancer Institute (NCI)· Updated 21 Jan 2026

  “This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Merck Sharp & Dohme LLC· Source

• Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

  NCT06865677· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 65
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 15

• Bulk and single cell RNA sequencing data reveal lactylation-related gene signatures for prognosis and immunity in cervical cancer.

  Braz J Med Biol Res, Aug 2026

• Tumor Core-Edge Divergence in T-Cell Exhaustion and Clonal Expansion in HPV-Related Cervical Squamous Cell Carcinoma Unveiled by Simultaneous Single-Cell RNA and TCR Sequencing.

  J Med Virol, Apr 2026

• Integrated single-cell and bulk RNA sequencing unravels neutrophil heterogeneity and validates SPP1 as a prognostic biomarker in cervical cancer.

  BMC Cancer, Jan 2026

• Single-Cell Sequencing Combined with RNA Sequencing Reveals the Role of Natural Killer Cells in Prognosis and Immunotherapy Response in Cervical Squamous Cell Carcinoma.

  Crit Rev Immunol, Jan 2026

• Single-Cell RNA Sequencing Analysis Reveals Correlation Between Immune Cell Composition and Gene Expression in Cervical Cancer.

  J Cell Mol Med, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.